The gastroesophageal cancer market (including gastric, gastroesophageal junction, and esophageal cancer) is witnessing a substantial change, largely fueled by the entry of immune checkpoint inhibitor combination therapies. We expect that label expansions of Opdivo (Bristol Myers Squibb) and Keytruda (Merck & Co.), as well as approvals of other programmed death-ligand 1 (PD-L1) and programmed cell death-1 (PD-1) inhibitors, will continue to reshape the human epidermal growth factor receptor-2 (HER2)-negative gastroesophageal cancer market in the coming years. Immune checkpoint inhibitors in combination with HER2-targeted agents and chemotherapy, and the anti-HER2 antibody-drug conjugate Enhertu (Daiichi Sankyo / AstraZeneca) are poised to expand treatment options for HER2-positive patients. Other treatments are targeting niche biomarkers (e.g., claudin18.2, FGFR2b) and are set to provide novel treatment options for select gastroesophageal cancer patients. Given the intense late-phase pipeline activity, we anticipate the approval of several new therapies for gastroesophageal cancer during the forecast period.
Questions answered
How is gastroesophageal cancer segmented by subpopulation, and how will the recent drug approvals and label expansions to the various subpopulations impact the market?
What are the key current therapies in gastroesophageal cancer, and how are they positioned in the treatment algorithm?
Which emerging therapies are the most promising, and how will they shape the future of the gastroesophageal cancer market?
What are the drivers and constraints in the gastroesophageal cancer market, and how will the market evolve over the forecast period?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Major-market share of drug classes in gastroesophageal cancer: 2021
Major-market share of drug classes in gastroesophageal cancer: 2031
Major-market sales of key therapies for gastroesophageal cancer: 2021-2031
Drug-treatable population share and major-market sales share in gastroesophageal cancer: 2021
Drug-treatable population share and major-market sales share in gastroesophageal cancer: 2031
Population positioning of therapies in gastric and GEJ cancer: United States and Europe
Population positioning of therapies in gastric and GEJ cancer: Japan
Population positioning of therapies in esophageal cancer: United States and Europe
Population positioning of therapies in esophageal cancer: Japan
Gastroesophageal cancer SWOT analysis
Market drivers and constraints
What factors are driving the market for gastroesophageal cancer?
What factors are constraining the market for gastroesophageal cancer?
Segment-specific trends
Patient-share dynamics of key regimens in resectable gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
Patient-share dynamics of key regimens in resectable esophageal cancer in the United States: 2021-2031
Patient-share dynamics of key regimens in unresectable locally advanced HER2-negative gastric and GEJ adenocarcinoma in the United States: 2021-2031
Patient-share dynamics of key regimens in unresectable locally advanced HER2-positive gastric and GEJ adenocarcinoma in the United States: 2021-2031
Patient-share dynamics of key regimens in unresectable locally advanced esophageal cancer in the United States: 2021-2031
Patient-share dynamics of key regimens in first-line metastatic HER2-negative gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
Patient-share dynamics of key regimens in first-line metastatic HER2-positive gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
First-line metastatic esophageal adenocarcinoma and squamous cell carcinoma
Patient-share dynamics of key regimens in first-line metastatic esophageal adenocarcinoma in the United States: 2021-2031
Patient-share dynamics of key regimens in first-line metastatic esophageal squamous cell carcinoma in the United States: 2021-2031
Patient-share dynamics of key regimens in second-line metastatic HER2-negative gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
Patient-share dynamics of key regimens in second-line metastatic HER2-positive gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
Patient-share dynamics of key regimens in second- and third-line metastatic esophageal adenocarcinoma in the United States: 2021-2031
Patient-share dynamics of key regimens in second- and third-line metastatic esophageal squamous cell carcinoma in the United States: 2021-2031
Patient-share dynamics of key regimens in third- and fourth-line metastatic HER2-negative gastric and gastroesophageal junction adenocarcinoma in the United States: 2021-2031
Patient-share dynamics of key regimens in third- and fourth-line metastatic HER2-positive gastric and gastroesophageal junction adenocarcinoma in the United States: 2020-2030
Forecast
Market forecast assumptions
Market forecast dashboard
Etiology and pathophysiology
Disease overview
Disease pathophysiology
Anatomy of the stomach and the gastroesophageal junction
Anatomy of the esophagus
Subtype classification and development of gastric and gastroesophageal junction adenocarcinoma
Key stages in the development of intestinal and diffuse types of gastric andu00a0gastroesophageal junctionu00a0adenocarcinoma
Subtype classification and development of esophageal cancer
Key stages in the development of esophageal cancer
Staging and classification
AJCC / UICC TNM classification system for gastroesophageal cancer
AJCC / UICC clinical staging classification system for gastroesophageal cancer
AJCC / UICC pathological staging classification system for gastroesophageal cancer
AJCC / UICC postneoadjuvant therapy staging classification system for gastroesophageal cancer
Key pathways and drug targets
Drug targets and potential therapies for gastroesophageal cancer
Drug targets for gastroesophageal cancer
Biology of immune checkpoint inhibitors and modulators
Epidemiology
Introduction
Key findings
Epidemiology populations
Disease definition
Methods and sources used
Number of diagnosed incident cases of gastroesophageal cancer: 2021-2031
Definition
Methods and sources used
Diagnosed incident cases of gastric and GEJ adenocarcinoma by stage distribution: 2021-2031
Diagnosed incident cases of esophageal adenocarcinoma by stage distribution: 2021-2031
Diagnosed incident cases of esophageal squamous cell carcinoma by stage distribution: 2021-2031
Definition
Methods and sources used
Recurrent incident cases of gastroesophageal cancer: 2021-2031
Definition
Methods and sources used
Molecular subtype: 2021-2031
Gastric and gastroesophageal junction adenocarcinoma patient flow
Esophageal adenocarcinoma patient flow
Esophageal squamous cell carcinoma patient flow
Drug-treatable cases of gastroesophageal cancer: 2021-2031
Drug-treated populations
Drug-treated cases of gastroesophageal cancer: 2021-2031
Current treatment
Key findings
Treatment goals
Key endpoints used in clinical trials for gastroesophageal cancer
Key current therapies
Overview
Mechanism of action of key current drug classes used for gastroesophageal cancer
Current treatments used for gastroesophageal cancer
Market events impacting the use of key current therapies for gastroesophageal cancer
Key results from select clinical trials investigating Cyramza for the treatment of gastroesophageal cancer
Ongoing clinical development of Cyramza
Key ongoing clinical trials of Cyramza in the treatment of gastroesophageal cancer
Expert insight: Cyramza
Key results from select clinical trials investigating trastuzumab for the treatment of gastroesophageal cancer
Ongoing clinical development of trastuzumab
Expert insight: trastuzumab
Key results from select clinical trials investigating Enhertu for the treatment of gastroesophageal cancer
Ongoing clinical development of Enhertu
Key ongoing clinical trials of Enhertu in the treatment of gastroesophageal cancer
Expert insight: Enhertu
Key results from select clinical trials investigating Keytruda for the treatment of gastroesophageal cancer
Ongoing clinical development of Keytruda
Key ongoing clinical trials of Keytruda in the treatment of gastroesophageal cancer
Expert insight: Keytruda
Key results from select clinical trials investigating Opdivo for the treatment of gastroesophageal cancer
Ongoing clinical development of Opdivo
Key ongoing clinical trials of Opdivo in the treatment of gastroesophageal cancer
Expert insight: Opdivo
Lonsurf
Key results from select clinical trials investigating Lonsurf for the treatment of gastroesophageal Cancer
Ongoing clinical development of Lonsurf
Expert insights: Lonsurf
Medical practice
Localized and resectable locally advanced gastroesophageal cancer
Unresectable locally advanced gastroesophageal cancer
First-line metastatic gastroesophageal cancer
Second-line gastroesophageal cancer
Patient characteristics influencing drug selection in gastroesophageal cancer
Region-specific treatment practices
Treatment decision tree for drug-treatable gastric and gastroesophageal junction adenocarcinoma: United States
Treatment decision tree for drug-treatable esophageal cancer: United States
Treatment decision tree for drug-treatable gastric and gastroesophageal junction adenocarcinoma: Europe
Treatment decision tree for drug-treatable esophageal cancer: Europe
Treatment Decision Tree for drug-treatable Gastric and Gastroesophageal Junction Adenocarcinoma: Japan
Treatment Decision Tree for drug-treatable Esophageal Cancer: Japan
Unmet need overview
Current and future attainment of unmet needs in gastroesophageal cancer
Top unmet needs in gastroesophageal cancer: current and future attainment
Expert insights: unmet need in gastroesophageal cancer
Drug pipeline
Pipeline
Regulatory Milestones
Indication Comparison
Emerging therapies
Key findings
Key emerging therapies
Key therapies in development for gastroesophageal cancer
Estimated market authorization dates of key emerging therapies for the treatment of gastroesophageal cancer
Key results from select clinical trials investigating tislelizumab for the treatment of gastroesophageal cancer
Key ongoing clinical trials of tislelizumab in the treatment of gastroesophageal cancer
Analysis of clinical development program for tislelizumab
Expert insight: tislelizumab
Expectations for market authorization and sales opportunity of tislelizumab in gastroesophageal cancer
Key results from select clinical trials investigating Imfinzi for the treatment of gastroesophageal cancer
Key ongoing clinical trials of Imfinzi in the treatment of gastroesophageal cancer
Analysis of clinical development program for Imfinzi
Expert insight: Imfinzi
Expectations for market authorization and sales opportunity of Imfinzi in gastroesophageal cancer
Key results from select clinical trials investigating Tecentriq / Tecentriq plus tiragolumab for the treatment of gastroesophageal cancer
Key ongoing clinical trials of Tecentriq / Tecentriq plus tiragolumab in the treatment of gastroesophageal cancer
Analysis of clinical development program for Tecentriq / Tecentriq plus tiragolumab
Expert insights: Tecentriq / Tecentriq plus tiragolumab
Expectations for market authorization and sales opportunity of Tecentriq / Tecentriq plus tiragolumab in gastroesophageal cancer
Key results from select clinical trials investigating Tyvyt for the treatment of gastroesophageal cancer
Key ongoing clinical trials of Tyvyt in the treatment of gastroesophageal cancer
Analysis of clinical development program for Tyvyt
Expert insights: Tyvyt
Expectations for market authorization and sales opportunity of Tyvyt in gastroesophageal cancer
Key results from select clinical trials investigating evorpacept for the treatment of gastroesophageal cancer
Key ongoing clinical trials of evorpacept in the treatment of gastroesophageal cancer
Analysis of clinical development program for evorpacept
Expectations for market authorization and sales opportunity of evorpacept in gastroesophageal cancer
Key results from select clinical trials investigating zanidatamab for the treatment of gastroesophageal cancer
Key ongoing clinical trials of zanidatamab in the treatment of gastroesophageal cancer
Analysis of clinical development program for zanidatamab
Expert insight: zanidatamab
Expectations for market authorization and sales opportunity of zanidatamab in gastroesophageal cancer
Key results from select clinical trials investigating Margenza for the treatment of gastroesophageal cancer
Key ongoing clinical trials of Margenza in the treatment of gastroesophageal cancer
Analysis of clinical development program for Margenza
Expectations for market authorization and sales opportunity of Margenza in gastroesophageal cancer
Tukysa
Key ongoing clinical trials of Tukysa in the treatment of gastroesophageal cancer
Analysis of clinical development program for Tukysa
Expert insight: Tukysa
Expectations for market authorization and sales opportunity of Tukysa in gastroesophageal cancer
Key results from select clinical trials investigating rivoceranib for the treatment of gastroesophageal cancer
Analysis of clinical development program for rivoceranib
Expert insight: rivoceranib
Expectations for market authorization and sales opportunity of rivoceranib in gastroesophageal cancer
Key results from select clinical trials investigating Stivarga for the treatment of gastroesophageal cancer
Key ongoing clinical trials of Stivarga in the treatment of gastroesophageal cancer
Analysis of clinical development program for Stivarga
Expert insight: Stivarga
Expectations for market authorization and sales opportunity of Stivarga in gastroesophageal cancer
Key results from select clinical trials investigating Lenvima for the treatment of gastroesophageal cancer
Key ongoing clinical trials of Lenvima in the treatment of gastroesophageal cancer
Analysis of the clinical development program for Lenvima
Expert insight: Lenvima
Expectations for market authorization and sales opportunity of Lenvima in gastroesophageal cancer
Key results from select clinical trials investigating zolbetuximab for the treatment of gastroesophageal cancer
Key ongoing clinical trials of zolbetuximab in the treatment of gastroesophageal cancer
Analysis of clinical development program for zolbetuximab
Expert insight: zolbetuximab
Bemarituzumab
Key results from select clinical trials investigating bemarituzumabu00a0for the treatment of gastroesophageal cancer
Key ongoing clinical trials of bemarituzumab in the treatment of gastroesophageal cancer
Analysis of clinical development program for bemarituzumabu00a0
Expert insight: bemarituzumab
Expectations for market authorization and sales opportunity of bemarituzumab in gastroesophageal cancer
Early-phase pipeline analysis
Select compounds in early-phase development for gastroesophageal cancer
Access and reimbursement overview
Region-specific reimbursement practices
Key market access considerations in gastroesophageal cancer: United States
General reimbursement environment: United States
Key market access considerations in gastroesophageal cancer: EU5
General reimbursement environment: EU5
Key market access considerations in gastroesophageal cancer: Japan
General reimbursement environment: Japan
Appendix
Abbreviations
Gastroesophageal cancer bibliography
Liseth Parra
Liseth Parra, Ph.D., is an analyst on the Oncology team at Clarivate. She has extensive background in oncology research and market analysis. She completed a postdoctoral fellowship in oncology at Brigham and Women’s Hospital in Boston, along with commercial work as an oncology research analyst for Kantar Health and as an independent consultant. She also worked as a research fellow at the Novartis Institutes for BioMedical Research in Basel, Switzerland, and at the Fritz Lipmann Institute in Jena, Germany. Dr. Parra completed her doctorate in neurosciences at the University of California in San Diego.
Narendra Parihar
Narendra Parihar, B.D.S., M.P.H., Senior Manager, Epidemiology. Dr Parihar is a team lead at Clarivate Epidemiology. He specializes in modelling and forecasting epidemiology patient populations across multiple indications. His primary areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. His qualifications include a master’s degree in public health with specialization in health policy, economics, and finance from Tata Institute of Social Sciences Mumbai, and a bachelor’s degree in dental surgery from the Rajasthan University of Health Sciences.